BRAF and melanoma: RCTs in untreated advanced melanoma were included if they used BRAF/MEK inhibitors or ICIs. The study aimed to indirectly compare ipilimumab/nivolumab and relatlimab/nivolumab, and these combinations versus other first-line treatments, assessing efficacy and safety.